Cargando…

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Musolino, Caterina, Allegra, Alessandro, Mannucci, Carmen, Russo, Sabina, Alonci, Andrea, Maisano, Valerio, Calapai, Gioacchino, Gangemi, Sebastiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451486/ https://www.ncbi.nlm.nih.gov/pubmed/26316486 http://dx.doi.org/10.4274/tjh.2014.0021

Ejemplares similares

The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox
por: Allegra, Alessandro, et al.
Publicado: (2019)

Commentary: Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD
por: Mannucci, Carmen, et al.
Publicado: (2019)

Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review
por: De Martinis, Massimo, et al.
Publicado: (2020)

The IL-33/IL-31 Axis in Allergic and Immune-Mediated Diseases
por: Murdaca, Giuseppe, et al.
Publicado: (2023)

Increased levels of interleukin 31 (IL-31) in osteoporosis
por: Ginaldi, Lia, et al.
Publicado: (2015)

Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
por: Murdaca, Giuseppe, et al.
Publicado: (2021)

Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023)

IL-33/IL-31 Axis: A Potential Inflammatory Pathway
por: Di Salvo, Eleonora, et al.
Publicado: (2018)

IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases
por: Murdaca, Giuseppe, et al.
Publicado: (2019)

Cannabinoids, Blood–Brain Barrier, and Brain Disposition
por: Calapai, Fabrizio, et al.
Publicado: (2020)

Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications
por: Allegra, Alessandro, et al.
Publicado: (2020)

Interleukin-33 serum levels in postmenopausal women with osteoporosis
por: Ginaldi, Lia, et al.
Publicado: (2019)

Safety of Medical Cannabis in Neuropathic Chronic Pain Management
por: Bennici, Alessandra, et al.
Publicado: (2021)

Microbiota and IL-33/31 Axis Linkage: Implications and Therapeutic Perspectives in Atopic Dermatitis and Psoriasis
por: Bonzano, Laura, et al.
Publicado: (2023)

Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies
por: Allegra, Alessandro, et al.
Publicado: (2021)

Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
por: Allegra, Alessandro, et al.
Publicado: (2022)

Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2022)

Cold Atmospheric Plasma Targeting Hematological Malignancies: Potentials and Problems of Clinical Translation
por: Gangemi, Sebastiano, et al.
Publicado: (2022)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
por: Calapai, Fabrizio, et al.
Publicado: (2022)

Nutraceuticals against Oxidative Stress in Autoimmune Disorders
por: Mannucci, Carmen, et al.
Publicado: (2021)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Specialized Intercellular Communications via Tunnelling Nanotubes in Acute and Chronic Leukemia
por: Allegra, Alessandro, et al.
Publicado: (2022)

Flare Up Reaction During Provocation Test to Glatiramer Acetate in a Patient With Allergy to Interferon Beta1a
por: Minciullo, Paola L., et al.
Publicado: (2014)

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Ageing is a risk factor in imatinib mesylate cardiotoxicity
por: Maharsy, Wael, et al.
Publicado: (2014)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Clinical Pharmacology of Citrus aurantium and Citrus sinensis for the Treatment of Anxiety
por: Mannucci, Carmen, et al.
Publicado: (2018)

IL-31, itch and hematological malignancies
por: Di Salvo, Eleonora, et al.
Publicado: (2021)

Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2019)

Bergamottin and 5-Geranyloxy-7-methoxycoumarin Cooperate in the Cytotoxic Effect of Citrus bergamia (Bergamot) Essential Oil in Human Neuroblastoma SH-SY5Y Cell Line
por: Maugeri, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eah01sjnavv16gv5f5pc3uoj7s